Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
about
Fucoidan and cancer: a multifunctional molecule with anti-tumor potentialAnnual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival.Outcomes of first line chemotherapy in patients with chronic lymphocytic leukemiaA phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesTrends in quality of non-Hodgkin's lymphoma care: is it getting better?Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis.A novel placental like alkaline phosphatase promoter driven transcriptional silencing combined with single chain variable fragment antibody based virosomal delivery for neoplastic cell targeting [corrected].Hairy cell leukemia - immunotargets and therapiesDevelopment of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential.Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma.Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma.Aptamer Internalization via Endocytosis Inducing S-Phase Arrest and Priming Maver-1 Lymphoma Cells for Cytarabine Chemotherapy.Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.Inhibition of Oncogenic Transcription Factor REL by the Natural Product Derivative Calafianin Monomer 101 Induces Proliferation Arrest and Apoptosis in Human B-Lymphoma Cell Lines.Delivering safer immunotherapies for cancer.The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin.The role of B cell antigen receptors in mantle cell lymphoma.Current Progress in EBV-Associated B-Cell Lymphomas.A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models.International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab.Racial differences in three major NHL subtypes: descriptive epidemiology.Biosimilars Have Arrived: Rituximab.Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL).
P2860
Q27021858-B71D0DE9-4C4C-4AD6-B5C3-21600323D15FQ30847275-39989B63-FE28-46BE-B81A-355F97EA61AFQ33437042-E972C4E1-9034-4524-BFA6-01344FA4CCE6Q33626106-9B0A65A1-AFAD-4CAB-AB99-3F76FFAFB351Q33665611-C0EED8FA-44A4-4374-8702-EC20FCC105C7Q35607583-1E5A604E-1A1F-40BA-95D3-2552673BAFCFQ35867011-0F5AA23D-4960-4995-B85C-2D5A6890770AQ35914149-350D166F-31BD-4C81-9CA8-030D92ADD288Q37031666-7A7391D9-78D6-4055-8766-5AF8243A197BQ37212371-F3343716-2623-4F20-A87C-08570BCF458DQ37641045-502759BE-8BCF-4AAD-9EAB-E51EBB0BE1F6Q37650735-23CB5BAA-0AD5-4DF1-A1CF-99C5122091D6Q37738158-0FC6B065-70EC-4D77-89C3-AA7155410CA1Q38288291-746D6305-AC4D-4FE4-B263-3C46B0680BF8Q38795442-B8165145-BE84-46BC-830A-1B115B73B9AAQ38882017-29A4ADB7-5E38-45AC-8CB9-0E89E6E55C71Q39330984-3A59F112-2184-472E-95FC-8CC4AAFBE4CAQ40182196-C39781EA-C76A-484E-A85D-41A69C945589Q42112255-BC8E8396-6A2F-46AE-8300-3D81C3BEB93FQ42682371-06A4E5DC-0629-44BA-A6B9-FDABB8263063Q47606345-39342309-E8D2-43DF-897F-1086F357DC5BQ49416991-1CC40648-66BB-44B4-B89E-05FFE5B16D65Q51793470-0C808264-FC61-4FEE-9751-147AC1A945B1Q53652438-0F03A830-54C6-41AD-98C0-5ECBB40917FCQ55105693-B5F4CD0B-027A-4FE5-A446-C2B3AD8C43D8Q55424824-9EA18BEC-1BAD-4849-B29A-2D5373131D22
P2860
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
@ast
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
@en
Impact of Rituximab
@nl
type
label
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
@ast
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
@en
Impact of Rituximab
@nl
prefLabel
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
@ast
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
@en
Impact of Rituximab
@nl
P2093
P2860
P1476
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
@en
P2093
Charu Aggarwal
Efrat Dotan
Mitchell R Smith
P2860
P304
P577
2010-03-01T00:00:00Z